Notes
NCT00524537
Reference
D'Haens G, et al. Lymphoma Risk and Overall Safety Profile of Adalimumab in Patients With Crohn's Disease With up to 6 Years of Follow-Up in the Pyramid Registry. American Journal of Gastroenterology : 5 Jun 2018. Available from: URL: http://doi.org/10.1038/s41395-018-0098-4
Rights and permissions
About this article
Cite this article
Safety of adalimumab in patients with Crohn's disease. Reactions Weekly 1708, 13 (2018). https://doi.org/10.1007/s40278-018-48106-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-018-48106-3